Trials / Terminated
TerminatedNCT06106841
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Phase Ib/II Clinical Trial of TQB3909 Tablets in Subjects With Relapsed or Refractory MCL Safety and Efficacy
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to assess the safety of TQB3909 monotherapy in participants with relapsed or refractory MCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 400mg of TQB3909 tablets | TQB3909 tablets 400mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor. |
| DRUG | 600mg of TQB3909 tablets | TQB3909 tablets 600mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor. |
Timeline
- Start date
- 2023-10-05
- Primary completion
- 2024-10-16
- Completion
- 2024-10-16
- First posted
- 2023-10-30
- Last updated
- 2025-12-30
Locations
28 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06106841. Inclusion in this directory is not an endorsement.